Recently, WUXI EXTPURE SOLUTIONS Co., Ltd. (WUXI EXTPURE) announced that it has signed a technology development agreement with Prof. Yongyou Zhang from the School of Life Sciences of Xiamen University (Xiamen University School of Biological Sciences), and established a joint R&D center, “Xiamen University School of Life Sciences-WUXI EXTPURE SOLUTIONS Co. SOLUTIONS Co., Ltd. to establish the “Affinity Ligand Design, Screening and Performance Evaluation Platform”. Background The AAV process package has become mature. The first step is to use affinity chromatography to capture viral products. AAV virus affinity chromatography products on the market include Thermo’s POROS™ CaptureSelect™ AAVX series and Repligen’s AVIPure® AAV series and Cytiva's Capto AVB series. Although the technology package has matured, there is still huge room for upgrading the captured affinity filler: . Although the affinity ligand shows strong virus capture ability and impurity removal effect, the product still has some problems in alkali resistance and versatility; . At the same time, coupling affinity ligands to macroporous microspheres or agarose packing also brings about the problems of low product yield, long purification process time and oversize of the purification packing column. Repligen acquired Taiwan's new Tantti to introduce ultra-large pore monolithic column preparation technology. One of its purposes is to provide a stronger carrier matrix for its existing AVIPURE® affinity ligand. For the LVV suspension process, there is no mature purification process scheme downstream, and conventional Capto Core and AEX series fillers are difficult to meet the requirements for product purity and yield. Affinity purification of LVV is a better choice, and Thermo Fisher has previously launched CaptureSelect™ Lenti VSVG captures LVV pseudotyped by VSVG, but the virus yield is very low due to issues with elution conditions and product retention. As an enveloped virus, the activity of LVV is greatly affected by the solution environment (pH, conductivity), temperature and process time. The development of affinity ligands requires high selectivity and mild elution conditions. In response to the above-mentioned industry pain points, WUXI EXTPURE cooperated with Xiamen University's Institute of Biological Sciences to develop affinity ligands including but not limited to AAV and LVV, and combined with the advantages of convection columns to accelerate the launch of affinity convection chromatography products. Research content 1. Design, development and verification of AAV affinity ligands 2. Design, development and verification of LVV affinity ligands 3. Design and development of exosomes and VLP affinity ligands Significance of the topic: Affinity convection chromatography-the best virus catcher With the cooperation between industry, academia and research institutes, WUXI EXTPURE product brand ACC® will surpass CaptureSelect and AVIPURE series. Based on the existing foundation, WUXI EXTPURE The ACC® product promotion plan is as follows: 2025Q2: Domestic promotion of AAV affinity series products; 2025 American Cytogenetic Society: Global promotion of AAV affinity series products. Both parties stated: “Xiamen University School of Life Sciences and WUXI EXTPURE SOLUTIONS Co., Ltd. The technology development cooperation marks a new starting point. Through joint research and development between industry, academia and research institutes, we will jointly build an advanced ‘affinity ligand design, screening and performance evaluation platform’ to inject new impetus into cell and gene therapy (CGT) purification technology. This is not only an important step in technological innovation, but also an important practice in promoting the development of the industry, bringing more breakthroughs and contributions to the future of the CGT field. " WUXI EXTPURE believes that through the close cooperation between the two parties and the integration of "AI + biology + materials + purification", ACC affinity convection chromatography will be accelerated to become the first brand of cell gene therapy purification.

On May 22-24, 2024, CGCS 2024 (the 5th) International Cell and Gene Therapy China Summit and Exhibition was grandly held at the Nanjing Yangtze River International Conference Center! As the highest-level annual conference in the fields of cell and gene therapy, nucleic acid drugs and organoids, this year's CGCS takes "innovation-driven, win-win cooperation" as its theme to jointly discuss the latest research results, technological progress and industry trends in cell and gene therapy. We encourage enterprises to innovate and deepen their development, enhance brand influence, and promote higher, faster, and stronger development of the industry. This conference gathered 200+ of the world's top speakers, 150+ mainstream exhibitors, and 5,000+ industry professionals participated offline. At the CGCS Awards Morning Star Award Ceremony on May 23, 2024, WUXI EXTPURE won the "Golden Star Award for Process and Production Solutions in the CGT Field" , thank colleagues in the industry for their recognition and support of WUXI EXTPURE. We will continue to work hard and innovate to bring more and better products to everyone.

WUXI EXTPURE SOLUTIONS Co., Ltd. announced that it has recently completed Pre-A round of financing. The financing was led by CDH Baifu and followed by the new team of Tin Venture Capital, and the funds will be used for product process research and development, marketing and commercial team building, and product commercialization and promotion. Founded in 2022, WUXI EXTPURE is a biotechnology company focusing on purification processes and materials in the field of cellular gene therapy. The company's core team comes from Tsinghua University and other well-known domestic and international universities, with interdisciplinary industrial background teams in physics, materials chemistry and biology. Adhering to the development principle of cross-border integration and re-innovation, WUXI EXTPURE has overcome the technical difficulties in the field of nucleic acid and virus purification, such as molds, hydrodynamics, material synthesis, bioengineering, chromatography theory, etc., and has realized a comprehensive layout from the “Wet Suspension and Polymerization of Microsphere Fillers” to the “Casting of Cellular Ceramic-like Molds”. We have realized an all-round layout from “wet suspension polymerization of microsphere filler” to “honeycomb-like ceramic mold”. WUXI EXTPURE is the first to propose a new generation of convective monolithic column solution - ACC (Affinity Convective Chromatography: “Extpure ACC” Leads CGT Purification), which is dedicated to challenging the difficulties of large-scale industrial purification of mRNA, gene therapy viral vectors, exosomes and other large-sized biomolecules. ACC (Affinity Convective Chromatography: “Extpure ACC” Leads CGT Purification) is dedicated to challenge the difficulty of large-scale industrial purification of large-sized biomolecules such as mRNA, gene therapy viral vectors, exosomes, etc., and to gradually realize better resolution, higher binding capacity, faster processing speed, and more economical packing cost. Meanwhile, in the field of traditional microsphere packing, the company will successively launch one-stop purification products and services, so that downstream customers have more optimal purification process options. In the field of nucleic acid/virus purification, there is no mature solution in the world, whether it is substrate, ligand or purification process package. WUXI EXTPURE challenges the industry's difficulties in a synchronized manner, and aspires to be the leading company in nucleic acid purification and virus purification: (1) Development of second-generation convection columns: achieving higher nucleic acid binding loads and better vesicular virus (lentivirus) fitness; (2) Rapid investment in affinity ligand development: provide higher binding load and faster processing speed, less packing optimization, allowing customers to complete the selection of downstream chromatography in one-stop. WUXI EXTPURE is developing alkali-resistant AAV affinity convection columns to provide customers with high-quality and high-efficiency AAV capture and purification products to compete with international giants in this field. For example, one of the international giants provides a cation exchange convection column for AAV purification with pH4.0~pH3.5 sampling, which poses a great risk of AAV inactivation quality. Another international giant's AAV affinity capture has become the best choice for the time being, but it also promotes its own relatively suboptimal choice - macroporous microsphere ion exchange purification, which can only accomplish solid enrichment, and whether the solid rate can satisfy 80% or even 90% in the future is a great doubt. The third international giant does not have a successful purification filler for lentivirus, AAV and mRNA. So far lentivirus purification is still using traditional virus vaccines mainly based on tangential flow filtration purification, decentralized product distribution, to the downstream brings great difficulty in product and process development. To break the superstition of the giants, the domestic industrial chain to achieve mutual success, DCPC will increase the product and process development, to provide downstream customers with one-stop purification products and services. (3) WUXI EXTPURE proposes a scalable lentivirus purification solution - Dual Affinity Convection Purification Process: Phospholipid Affinity + Pseudotyped Protein Affinity, which realizes the completion of the downstream purification process in 8 hours, and becomes a scalable platform process for the next generation of vesiculoviruses, so that highly efficient chromatography can be really efficient in lentivirus purification. WUXI EXTPURE is very grateful for the attention and support from CDH Baifu, XVC New Venture Team, and the old shareholder Quechen Silicon Chemical Co., Ltd.(605183.SH) to WUXI EXTPURE. The rapid development of the global biopharmaceutical industry has brought new opportunities and challenges for the rise of domestic upstream and downstream industry chain and going overseas, WUXI EXTPURE has been committed to challenging the difficulties and pain points in the field of purification, improving and laying out the enterprise's core technology in depth, planting new productivity and realizing the enterprise's high-quality development since its inception. In the new track, the domestic substitution is not the end, WUXI EXTPURE team to realize the cross-border to “integration - re-innovation” jump, for the biopharmaceutical industry purification to provide better solutions, so that the cell gene therapy to benefit more patients.